FIDFX
Price
$33.28
Change
+$0.47 (+1.43%)
Updated
Nov 5 closing price
VMVIX
Price
$65.94
Change
+$0.82 (+1.26%)
Updated
Nov 5 closing price
Ad is loading...

FIDFX vs VMVIX

Header iconFIDFX vs VMVIX Comparison
Open Charts FIDFX vs VMVIXBanner chart's image
Fidelity Advisor Mid Cap Value Z
Price$33.28
Change+$0.47 (+1.43%)
VolumeN/A
CapitalizationN/A
Vanguard Mid-Cap Value Index Investor
Price$65.94
Change+$0.82 (+1.26%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FIDFX vs VMVIX Comparison Chart
Loading...
VS
FIDFX vs. VMVIX commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FIDFX is a Buy and VMVIX is a Sell.

FUNDAMENTALS
Fundamentals
VMVIX has more cash in the bank: 31.2B vs. FIDFX (1.91B). VMVIX pays higher dividends than FIDFX: VMVIX (2.03) vs FIDFX (0.82). FIDFX was incepted earlier than VMVIX: FIDFX (8 years) vs VMVIX (18 years). FIDFX is a more actively managed with annual turnover of: 78.00 vs. VMVIX (22.00). FIDFX has a lower initial minimum investment than VMVIX: FIDFX (0) vs VMVIX (3000). FIDFX annual gain was more profitable for investors over the last year : 30.66 vs. VMVIX (25.57). FIDFX return over 5 years is better than : 55.49 vs. VMVIX (44.55).
FIDFXVMVIXFIDFX / VMVIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years18 years-
Gain YTD14.04214.31398%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.91B31.2B6%
Annual Yield % from dividends0.822.0340%
Returns for 1 year30.6625.57120%
Returns for 3 years12.9011.61111%
Returns for 5 years55.4944.55125%
Returns for 10 yearsN/A93.19-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LAUR17.300.40
+2.37%
Laureate Education
BXP80.331.17
+1.48%
BXP Inc.
TTI3.26-0.02
-0.61%
TETRA Technologies
ANIX3.47-0.19
-5.19%
Anixa Biosciences
KTTA3.60-0.20
-5.26%
Pasithea Therapeutics Corp